

Surrogate marker for HPV infection in oropharyngeal carcinoma



p16^{INK4a}

p16^{INK4a} (clone G175-405)

Specifications	Volume	Cat. No.
<ul style="list-style-type: none">Species: mouseApplication: paraffin, frozenIsotype: IgG2Visualization: cytoplasmic, nuclearFor research use only (RUO)	1ml concentrate	Z2117





Numerous reports have shown, that the infection with certain types of HPV can increase the risk of cancer in various tissues.

At present, especially the incidence of HPV-related oropharyngeal cancers is increasing.¹ Several studies revealed, that in 30 – 80 % of all oropharyngeal carcinomas an HPV infection can be detected.²

HPV-related oropharyngeal carcinomas are characterized by a better response to therapy and a more favorable clinical outcome than HPV negative oropharyngeal carcinomas.³⁻⁶

Because of this prognostic relevance the assessment of the p16-status in oropharyngeal carcinoma is now included in the 8th edition of the TNM classification of malignant tumors.^{1,7}

The detection of a p16^{INK4a} expression by immunohistochemistry is considered as a reliable marker for a HPV-infection in oropharyngeal carcinoma and can serve as an independent prognostic marker.⁸



p16^{ink4a} (clone G175-405) on oropharyngeal carcinoma, provided as a courtesy by R  veyda Dok, KU Leuven, Dept. of Oncology.

HPV/p16 Cell Microarray Controls

Standardized and cost-effective reference material suitable for immunohistochemistry (IHC) and *In situ* hybridization (ISH).

Antigen	Product information	Format	Cat. No.
HPV/p16	3 cores, positive and negative for the HPV gene, E6/E7 mRNA and expression of the p16	2 OT 5 OT Block	HCL004 HCL005 HCL006
HPV/p16 ^{DR}	4 cores, dynamic range of HPV gene copies, E6/E7 mRNA levels and protein expression of p16l	2 OT 5 OT Block	HCL001 HCL002 HCL003

Other markers for Immunohistochemistry

Antigen	Clone	Species	Catalog number			
			Concentrate			RTU*
			0.1ml	0.5 ml	1.0 ml	7.0 ml
Bcl-2	124	mouse	226M-94	226M-95	226M-96	226M-98
Cyclin D1	SP4	rabbit	241R-14	241R-15	241R-16	241R-18
EBV	MRQ-47	rabbit	245R-14	245R-15	245R-16	245R-18
EGFR	EP22	rabbit	414R-24	414R-25	414R-26	414R-28
HPV, pan (L1-Kapsid)	BSB-66 (SB 24)	mouse	BSB 5655	BSB 5656	BSB 5657	BSB 5653
HPV 16	CAMVIR-1	mouse	BSB 2946	BSB 2947	BSB 2948	BSB 2944
HPV (Typ 6, 11, 16, 18, 31, 33, 42, 51, 52, 56, 58)	K1H8	mouse	-	-	Z2201	-
Ki-67	SP6	rabbit	275R-14	275R-15	275R-16	275R-18
p53	D07	mouse	BSB 5844	BSB 5845	BSB 5846	BSB 5842
Retinoblastoma (Rb)	1F8	mouse	BSB 6130	BSB 6131	BSB 6132	BSB 6128
Survivin	EP119	rabbit	BSB 2226	BSB 2227	BSB 2228	BSB 2224

*further sizes available

Literature

1. Lydiatt WM, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer stagingmanual: Head and Neck Cancers-Major 8th Edition Changes. CA Cancer J Clin. 2017; 67:122-137.
2. Ndiaye C, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014; 15:1319-1331.
3. Rischin D, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010; 28:4142-4148.
4. Ang KK & Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012; 22:128-142.
5. O'Rourke MA, et al. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol. 2012; 48:1191-1201.
6. Dok R, et al. Nuclear p16INK4a expression predicts enhanced radiation response in head and neck cancers. Oncotarget. 2016; 7:38785-38795.
7. Amin MB, et al. (eds.). American Joint Committee on Cancer Staging System, 8th Edition, Springer New York, 2017.
8. Sano D & Oridate N. The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol. 2016; 21:819-826.
9. Beadle BM. The impact of HPV testing for oropharyngeal cancers: Why the addendum matters. Cancer 2017; 125:301-302.



From visualisation
to diagnosis.

medac GmbH
Diagnostics

Theaterstraße 6
22880 Wedel
Germany

Telephone: +49 (0)4103 8006-342

Fax: +49 (0)4103 8006-359

E-mail: diagnostika@medac.de

www.medac-diagnostics.de



First-hand
information